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HPV.edu study protocol: a cluster randomised
controlled evaluation of education,
decisional support and logistical strategies
in school-based human papillomavirus
(HPV) vaccination of adolescents
S. Rachel Skinner1, Cristyn Davies1*, Spring Cooper2, Tanya Stoney3, Helen Marshall4, Jane Jones3, Joanne Collins4,
Heidi Hutton3, Adriana Parrella4, Gregory Zimet5, David G. Regan6, Patti Whyte7, Julia M. L. Brotherton8,
Peter Richmond3,13, Kirsten McCaffrey9, Suzanne M. Garland10, Julie Leask9, Melissa Kang11,
Annette Braunack-Mayer12, John Kaldor6 and Kevin McGeechan9
Abstract
Background: The National Human Papillomavirus (HPV) Vaccination Program in Australia commenced in 2007 for
females and in 2013 for males, using the quadrivalent HPV vaccine (HPV 6,11,16,18). Thus far, we have demonstrated
very substantial reductions in genital warts and in the prevalence of HPV among young Australian women, providing
early evidence for the success of this public health initiative. Australia has a long history of school-based vaccination
programs for adolescents, with comparatively high coverage. However, it is not clear what factors promote success in a
school vaccination program. The HPV.edu study aims to examine: 1) student knowledge about HPV vaccination;
2) psycho-social outcomes and 3) vaccination uptake.
Methods/Design: HPV.edu is a cluster randomised trial of a complex intervention in schools aiming to recruit 40
schools with year-8 enrolments above 100 students (approximately 4400 students). The schools will be stratified by
Government, Catholic, and Independent sectors and geographical location, with up to 20 schools recruited in each of
two states, Western Australia (WA) and South Australia (SA), and randomly allocated to intervention or control (usual
practice). Intervention schools will receive the complex intervention which includes an adolescent intervention
(education and distraction); a decisional support tool for parents and adolescents and logistical strategies (consent form
returns strategies, in-school mop-up vaccination and vaccination-day guidelines). Careful process evaluation including
an embedded qualitative evaluation will be undertaken to explore in depth possible mechanisms for any observed
effect of the intervention on primary and secondary outcomes.
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Discussion: This study is the first to evaluate the relative effectiveness of various strategies to promote best practice in
school-based vaccination against HPV. The study aims to improve vaccination-related psychosocial outcomes,
including adolescent knowledge and attitudes, decision-making involvement, self-efficacy, and to reduce fear and
anxiety. The study also aims to improve school vaccination program logistics including reduction in time spent
vaccinating adolescents and increased number of consent forms returned (regardless of decision). Less anxiety in
adolescents will likely promote more efficient vaccination, which will be more acceptable to teachers, nurses and
parents. Through these interventions, it is hoped that vaccination uptake will be increased.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12614000404628, 14.04.2014.
Background
With several countries having now implemented HPV
vaccination programs, data on uptake are beginning to
emerge. Although the age range for comparison varies
internationally, there is a vast difference in HPV vaccine
uptake across these countries, from very high—86.7 %
for 3 doses in adolescent females of the target age in the
UK (2013–2014) [1]—to very low—37 % for 3 doses
among the adolescent age group in the US [2]. Uptake
needs to be consistently high for a comprehensive reduc-
tion in HPV disease burden to be achieved at a
population-level. In particular, if 3-dose vaccination
coverage can be increased from 67 to 90 %, models pre-
dict that the long-term reduction in incident infection
will be increased from 76 to 95 % [3]. In general, school-
based programs tend to have higher coverage than non-
school based programs [4].
The National HPV Vaccination Program in Australia
commenced school delivery in April 2007 for girls and
February 2013 for boys, using the quadrivalent HPV
[qHPV] vaccine. The routine cohort for vaccination is
age 11–14 years (year 7 or 8 in secondary school de-
pending on jurisdiction). The HPV vaccine is offered
alongside other vaccines in the national school vaccin-
ation program (e.g. Diphtheria, Tetanus and Pertussis
(DTaP) booster and varicella vaccines). In Australia, the
National HPV Vaccination Program Register reports that
for girls aged 14–15 years of age (as of mid-2012), 82 %
received HPV dose 1, 78 % received HPV dose 2, and
71 % received HPV dose 3 (2013) [5].
Strategies for school-based vaccination
In Australia, a school-based delivery is used, and paren-
tal consent is required for the vaccination to proceed.
Schools distribute parental consent forms (with an infor-
mation brochure) to all eligible students to take home
for signing.1 However, students most often receive little,
or no, education about HPV or HPV vaccination prior
to immunisation [6, 7] and there is no requirement for
separate consent/assent from the adolescent. Perhaps
implicit is an expectation that parents will discuss the
vaccine and share information with their adolescent.
Where adolescents are absent on a school vaccination
day, or have not provided a signed consent form, they
can access vaccination through a local immunisation
clinic or their general practitioner.
There is little evidence available to guide strategies for
school-based vaccination. Our systematic review of prac-
tices for school-based vaccination implementation iden-
tified only one randomised controlled trial in 14 studies,
which evaluated process [8, 9]. We identified the import-
ance of well-designed vaccination education to promote
understanding, and strategies to promote return of con-
sent forms and to vaccinate students absent on school
vaccination days [10–12]. In addition, our qualitative re-
search in Sydney schools highlighted the importance of
procedural issues, as well as knowledge and attitudes, to
vaccination consent and completion [13–15].
Adolescents’ lack of knowledge and understanding about
the HPV vaccine in Australia
There is now clear evidence that many adolescents have
little or no understanding of the vaccines they receive or
the diseases they are intended to prevent. Our research
in Australian schools has shown that, adolescents’ un-
derstanding, self-efficacy, and involvement in decision-
making regarding HPV vaccination are low, and that
their fear and anxiety are high [6, 14, 15]. Further, even
after widespread media promotion, participation in the
consent process and experiencing vaccination, there was
still a low level of knowledge among adolescents in
Australia [6, 16, 17]; and even internationally despite
high vaccination rates [18, 19]. Despite media awareness
campaigns, there is also some uncertainty about where
adolescents can and should obtain reliable information
about the vaccine [6, 20].
Adolescent experience of needle related anxiety with
vaccination
We have previously described significant adolescent anx-
iety associated with HPV vaccination in the school-
based setting [15, 21] from adolescent, parent and nurse
reports as well as vaccination-day observations, and
international studies reveal similar and related concerns
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[18, 22]. We identified a range of strategies from our
previous research, including: education of students about
HPV and HPV vaccination prior to vaccination day; vac-
cinating adolescents in the morning so that they are not
waiting all day; use of privacy screens during vaccin-
ation; bringing adolescents to the vaccination area in
small groups to avoid extended waiting times; having a
separate entrance and exit point so that vaccinated ado-
lescents do not have contact with those still waiting; dis-
traction techniques such as iPod use while waiting for
vaccination, and relaxation techniques such as breathing
exercises learned prior to vaccination day, which may re-
duce vaccination related anxiety [13, 15, 21].
Parent and adolescent HPV vaccination decision making
We previously described HPV vaccination decision-
making by parents and adolescents in a school setting
[14]. We identified that parents face challenges discuss-
ing HPV and vaccination with their adolescents, and ad-
olescents rarely participate in decision-making [14]. This
situation is not optimal for several reasons, including:
the missed opportunity for adolescents and parents to
effectively communicate about important health issues
and to support adolescents developing autonomy; there
are important ethical reasons why adolescents should
participate in consent processes regarding their own
health [7, 21, 23]. For the school-based vaccination con-
text, there are currently no tools to support an informed
decision-making process that can be shared between
parents and adolescents.
In this paper we describe the protocol of our cluster
randomised controlled evaluation of decisional support and
logistical strategies in school-based Human Papillomavirus
(HPV) Vaccination of adolescents.
Trial aims
The study aims to examine: 1) student knowledge about
HPV vaccination; 2) psycho-social outcomes and 3) vac-
cination uptake.
Trial methods
Study design
Cluster randomised controlled trial occurring over two
school years: 2013 and 2014.
Sample
The overall target sample is 40 schools with year-8
enrolments above 100 students, stratified by Govern-
ment, Catholic, and Independent sectors and geo-
graphical location, with up to 20 schools recruited in
each of two states, Western Australia (WA) and South
Australia (SA).
Setting
The greater metropolitan area of Perth, WA, and
Adelaide, SA.
Participants
Male and female students in their first year of high
school (year 8 in participating states). Key school
personnel in participating schools and immunisation
nurses.
Advisory board
An Advisory Board exists that includes representatives
from the government, Catholic and Independent educa-
tion authorities and from health department and im-
munisation teams in both study jurisdications. The
purpose of this Advisory Board is to advise on all as-
pects of the study. The board will meet regularly prior
to study initiation and during the study with email
communication throughout.
Ethics and informed consent
We obtained ethical approval from the Department of
Health WA Human Research Ethics Committee and
Women’s and Children’s Hospital (WCHN) Human Re-
search Ethics Committee. Approval was also obtained
from the relevant WA and SA government authorities.
We sought approval for a consent waiver from parents
for the evaluation of this study [24]. In Australia, Human
Research Ethics Committees may grant consent waivers
when: involvement in the research carries no more than
low risk; the benefits from the research outweigh the
risk of harm from not seeking consent; participants
would be expected to consent if asked; confidentiality is
maintained; and attempts to obtain consent are very un-
likely to lead to adequate response rates. These condi-
tions all held for this research project and, accordingly,
the project was granted ethical approval [25].
Randomisation
Permuted block randomisation
Schools will be stratified by state (WA or SA) and sector
(Government, Independent single-sex, Independent coed-
ucational, Catholic single-sex, Catholic co-educational)
and within strata, randomised using permuted blocks.
Randomisation lists will be created using the software pro-
gram Rand.exe [26]. The researchers recruiting schools
and the contact people at the schools will be blind to
which arm of the trial the school will be allocated to at the
time the school agrees to take part in the study. The trial
statistician, who will have no involvement in recruitment,
will allocate schools using the randomisation list after the
school has agreed to take part. Schools will be allocated
according to the list in the order in which they are re-
cruited. Where possible, schools will not be allocated until
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the target number in the strata is reached. After the school
is allocated, recruiters and schools will no longer be blind
to intervention/control status.
Intervention
The intervention consists of three main components: 1)
an adolescent intervention; 2) an HPV vaccine parent/
adolescent decision support tool; and 3) logistical strat-
egies. The adolescent intervention is designed to pro-
mote knowledge, decision-making involvement and
confidence in vaccination (self-efficacy) and reduce
vaccination-related anxiety in adolescents. The deci-
sional support tool is designed for use by both adoles-
cents and parents together to promote understanding
and shared decision-making. Logistical strategies are de-
signed to improve vaccination uptake, school vaccination
processes and the adolescent experience. The interven-
tion components are outlined in further detail below:
1) The adolescent intervention comprises: education
taught through the school in an interactive lesson
(see Additional file 1); a take-home magazine designed
by and for adolescents; online components that can
be accessed outside the school in a website and app
for mobile devices; and distraction/relaxation methods
to be used prior to and during vaccination, supported
by nurses and teachers.
Further information on the development of the
adolescent intervention is detailed in a separate
publication [27]. Briefly, education occurs via an
18 min animated film (on DVD) about HPV and HPV
vaccination with seven chapters including: HPV- the
virus; HPV vaccination; males and HPV; decision-
making about HPV vaccination; what happens on the
school vaccination day; cervical screening into the
future. The film is designed to be screened in class, in
an interactive way, with school personnel. A teacher
user guide and supplement containing educational
activities for each chapter accompany the DVD and
other resources.
The magazine includes a range of practical
information about HPV and HPV vaccination, and
the school vaccination day, in an appealing format.
The magazine is designed to be taken home by
students to read in their own time.
A website (http://takechargehpv.org) and an app for
mobile devices, including all educational resources
will be available for students in intervention schools,
to use in a flexible way. The website includes
information about HPV and HPV vaccination and is
intended to reinforce the information taught in
class. Adolescents can re-watch the film clips, sign
up to receive reminders about vaccination, and share
their stories about being vaccinated.
iPads will be available for use on vaccination day to
assist with relaxation and distraction and will
contain only the study app, which incorporates
information from the website, the film chapters, the
magazine, and relaxation exercises and distraction
activities such as a painting tool.
2) A HPV vaccination decisional support tool (DST)
designed for use by both adolescents and parents
together in the home environment is being used in the
study. It has been developed using input from parents
and adolescents [28]. We have an evidence-based deci-
sion aid, developed according to internationally accepted
standards for presenting balanced information about
health care options [29]. This was tested and refined
after input from male and female adolescent-parent
dyads obtained in interviews [28]. This decision aid also
incorporates innovative methods to facilitate discussion
of sensitive topics and shared decision-making.
3) Logistical strategies will include methods for increasing
consent form return such as direct mail-out of forms
to parents (rather than being delivered to parents by
adolescents); reminders (re-sending vaccination
consent forms when they have not been returned);
and non-material incentives for classroom consent
form return (such as homeroom points) regardless of
whether parental consent is granted. In addition,
guidelines for nurses and teachers about the set-up
of the vaccination room to minimise student
anxiety, promote student privacy, and assist with
the efficiency of vaccination processes (see Additional
file 2), and distraction strategies to directly assist
the management of adolescent anxiety will be
implemented. In-school ‘mop-up’ vaccination for
students who have a valid consent but were absent
on a previous vaccination day will be provided both
on standard vaccination days and through one
additional visit per school after dose 3.
Training of staff to implement intervention
Prior to the commencement of the study in a school,
study staff will offer training to school personnel in the
educational and logistical components of the study. Dur-
ing this training a checklist of study activities will be
provided to the coordinating staff member and dis-
cussed. A similar training session will also be completed
with each of the school-based immunisation teams be-
fore the first vaccination day.
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Measure
HPV adolescent questionnaire (HAVIQ)
We have developed and validated a questionnaire (meas-
ure) to determine changes in adolescent knowledge, atti-
tudes, fear and anxiety, self-efficacy, and decision-making
[28]. The items in this measure have been informed by a
review of existing questionnaires around HPV [30–34],
the results of our own research [6, 7, 8, 13, 23], and an ex-
pert panel of academics working in related fields. The do-
mains of the measure include: HPV and HPV vaccine
knowledge and attitudes; HPV-related fear and anxiety
‘Feelings towards vaccination’; involvement in HPV
vaccination decision-making; and HPV vaccination self-
efficacy ‘Skills inventory’. Knowledge and attitudes,
‘Feelings towards vaccination’ and decision making
involvement were measured with a series of questions
(6, 6, and 8, respectively) each coded on a Likert scale
(strongly agree to strongly disagree and scored 1–5);
Skills inventory (5 questions) using a confidence scale
from 0 to 100. The measure has been tested for face and
content validity and internal consistency and test/re-test
reliability. The questionnaire has been tested in six
schools to determine preliminary impact on knowledge,
vaccination self-efficacy and fear [35].
Data collection
Psychosocial outcomes will be measured using the HPV
Adolescent Vaccination Intervention Questionnaire
(HAVIQ). School personnel will administer the entire
HAVIQ questionnaire (all four domains) after the stu-
dents have participated in the education intervention
session, but before they have had dose 1 of the HPV vac-
cine in intervention schools, and prior to dose 1 in con-
trol schools. Both groups of schools will complete the
‘Skills inventory’ and ‘Feelings towards vaccination’ com-
ponents of the questionnaire before dose 2 of the HPV
vaccine to measure the change in these domains after
personal experience with vaccination. The ‘Knowledge’
component of the questionnaire will be given again prior
to dose 3 of the HPV vaccine to measure knowledge re-
tention over time. Self-reported vaccination status will
be included in the questionnaire prior to dose 3.
Vaccination uptake
We will obtain de-identified school-level immunisation
uptake data from each State’s Health Department. De-
identified student vaccination data will be linked to
questionnaire data via codes generated by participating
schools’ administration.
Time taken to immunise
This will be documented by the school-based immunisa-
tion nurses on the study “School-based Immunisation
Log for Nursing Staff” on each vaccination day. The start
and end time will be recorded, as well as the total num-
ber of hours/minutes spent vaccinating the students, ex-
cluding any breaks.
Standard procedures for vaccination in all schools
Consent for vaccination forms will be sent out as per
normal operating procedures described in the relevant
state guidelines. Vaccination Room set-up: Room set up
to follow normal operating procedures described in
relevant state guidelines. Mop-ups: To follow normal
operating procedures described in relevant state
guidelines.
Statistical methods/analysis
Power calculation
To allow for the possibility of schools dropping out of
the study, we increased the number of schools by 10 %
and aimed to recruit a total of 40 schools. A total of 36
schools allows for the detection of a change in the per-
centage of students vaccinated from 70 to 80 % at a sig-
nificance level of 0.05 and with a power of 80 % and
assuming an intraclass correlation coefficient (ICC) of
0.05 [36]. We estimated the ICC from a pilot study in
NSW to be 0.04, and other cluster trials of adolescent
health behaviours have reported ICC’s of less than 0.05
[37]. We estimated, that on average, each school of the
36 schools would have 150 students giving a total final
sample size of 5400 students.
With a total of 36 schools, we will be able to detect the
following differences in means between the intervention
and control groups for the four secondary outcomes: 1)
Knowledge–minimum detectable difference “equals” =
0.7; 2) Fear/anxiety–minimum detectable difference
“equals” = 0.7; 3) Decision making–minimum detectable
difference “equals” = 0.5; 4) Skills inventory–minimum
detectable difference “equals” = 18; all assuming an ICC of
0.05, power of 80 %, significance of 0.05 and standard
deviations derived from a pilot study evaluating each of
these measures and allowing for a 40 % non-completion
of these outcomes [36, 37].
Primary outcome analysis
The primary analysis will compare vaccination rates
using the Mantel-Haenszel method, taking into account
the stratification by year, state and school sector and ad-
justed for clustering [36]. In addition, logistic regression
models will be used to adjust for baseline vaccination
rates (average of the previous 2 years), school type (sin-
gle-sex, or mixed), school size and SEIFA index using
generalized estimating equations (GEE) with robust
standard errors. The level of implementation of the
intervention will also be included.
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Secondary outcome analysis
Mean change in scores of knowledge, self-efficacy, fear/
anxiety, and decision-making will be compared between
groups using two-sample t-tests with appropriate adjust-
ment for clustering. Baseline scores for knowledge will
be taken from the control group. Proportion of consent
form returns will be compared between groups prior to
dose 1 using Chi-square test with appropriate adjust-
ment for clustering. Time taken to vaccinate will be
measured by nurses during each immunisation day in
both intervention and control schools. It will be calcu-
lated as the mean time to vaccinate 50 students in inter-
vention schools compared with control schools. Mean
time to vaccinate will be compared between groups in
both years of the study to determine effect of the inter-
vention over time. We will investigate whether the inter-
vention improves vaccination rates through its effect on
fear reduction, and self-efficacy increase, by comparing
estimates of the effect of the intervention both with and
without adjustment for the possible intermediary vari-
ables of fear/anxiety, and self-efficacy. These logistic re-
gression models will use GEE and robust standard errors
to account for the clustering.
Process evaluation
1) Implementation of intervention
Teachers and nurses logs: During the intervention,
school personnel and immunisation nurses will
complete study logs. The first log will document the
implementation of the education intervention to be
completed by school personnel, the second log will
document vaccination day processes to be
completed by immunization nurses, and the third
log will document logistics implemented and
observed by supervising school personnel on
vaccination day.
2) Qualitative evaluation
We will undertake this in a sub-sample of intervention
and control schools, which we term the ‘case-study
schools’. Data collection will include observations of
vaccination day, semi-structured interviews with
teachers, school nurses, immunisation nurses and
parents, and semi-structured focus groups with
students to provide a more in-depth understanding
of the mechanisms for change promoted by the
intervention. The interviews and focus groups will be
conducted primarily to explore the effects of the study
intervention and what aspects of the intervention are
most useful and what aspects are less useful. Qualitative
ethnographic methods have been used with success to
evaluate previous similar investigations [6, 14].
Six intervention schools and 6 control schools will
serve as case studies during the study. Case studies
are detailed analyses of persons, events, decisions,
projects, policies, institutions, programs,
interventions or other systems that are studied
holistically [38]. Case studies can draw on qualitative
and quantitative data to provide in-depth examples
of schools as sites in which knowledge, perceptions
and experiences of HPV and HPV vaccination are
effectively contextualised. This method will allow
better explanation of the effects of the intervention
by comparing and contrasting case studies.
We aim to recruit 6–10 students for at least one
focus group and 6–8 parents for one focus group or
at least 4 individual interviews in each case study
school. We will interview at least one school
personnel member and at least one immunisation
nurse for each selected school. If data collected from
one school is insufficient for data saturation, then an
additional school may be recruited.
All qualitative data will be digitally recorded, and
transcribed verbatim. The qualitative evaluation
aims to explore in depth possible mechanisms for
any observed effect of the intervention on primary
and secondary outcomes. We will analyse the
qualitative data using thematic and discourse
analysis [39–42].
Discussion
This study is unique for several reasons. The intervention
is multi-faceted and situated in the community, which fa-
cilitates direct translation to the real world. Rigorous
evaluation methods are used. A special strength of this
study is the use of qualitative data collection to provide
in-depth understandings of mechanisms of change.
Adolescents will be informed participants in vaccin-
ation. Further, this study will evaluate a novel tool to
promote adolescent and parental cooperation in vac-
cination decision-making. The intervention may im-
pact on uptake of other vaccines offered in the school
program, as aspects of the intervention are generic for
vaccines (such as consent form processes, mop up vac-
cination, and tools to promote self-efficacy and reduce
anxiety); educational resources could also be extended
to include the other vaccines offered, to maximize pub-
lic health benefit.
There is international interest in how to vaccinate the
young adolescent age group, as many countries are experi-
encing challenges in achieving HPV vaccination coverage
targets. Adolescents are outside the age range of most
established childhood vaccination programs. If this project
demonstrates an increase in adolescent knowledge and
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self-efficacy, improves decision involvement, and reduces
vaccine related anxiety, the findings of this study will be of
interest not only to the Australian school vaccination pro-
gram, but all countries.
Confidentiality of named data
The Principal Investigator or delegate will maintain source
documentation for every participant enrolled in the study
and all study forms for each enrolled participant will be
stored securely in locked cabinets and will only be
accessed by appropriately trained research staff. Any pub-
lications based on the data will only provide the allocated
pseudonym of the participant to protect their identity.
This will be the first study of its kind to provide an
evidence-based for successful school based vaccination
against HPV. This study should provide data on what in-
terventions support student knowledge and understand-
ing of HPV and vaccination, improve their involvement
in consent and decision-making (supporting their future
health autonomy), and improve their experience of vac-
cination. Building on the complexity of the intervention,
we should be able to determine which logistical strategies
improve vaccination uptake in school-based vaccination.
These data will provide essential evidence going forward
to support the use of school based platforms for delivery
of vaccination to adolescents. It will also provide detailed
guidance to other countries that are considering utilis-
ing schools to offer vaccination to adolescents for the
first time. There is huge international interest in how
to vaccinate the young adolescent age group given the
enormous potential for future health benefit. This is a
challenge for many countries as adolescents are out-
side the age range of most established childhood vac-
cination programs; without appropriate vaccination
delivery systems in place, such as effective school
based vaccination, uptake will not come close to the
desired targets.
Endnotes
1In each state and territory of Australia, parents are
supplied with a fact sheet with information about all the
vaccines offered through the national school based
vaccination program.
Additional files
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